Undescended Testis Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Orchidopexy (or orchiopexy) is the surgical procedure that brings an undescended testis (cryptorchidism) from its abnormal position into the scrotum and fixes it there permanently. Cryptorchidism — the failure of one or both testes to descend into the scrotal sac before birth — is the most common genital abnormality in male infants, affecting approximately 3–5% of full-term newborns and up to 30% of premature males. In the majority, spontaneous descent occurs by 3 months of age (often within the first year), reducing prevalence to 1% by 12 months. Testes that have not descended by 6 months corrected gestational age are unlikely to descend spontaneously. The testis descends from its developmental position near the kidney through the inguinal canal into the scrotum during foetal development; arrest can occur at any point along this pathway — most commonly in the inguinal canal (72%), at the superficial inguinal ring (20%), in the abdomen (8%), or at ectopic locations. Orchidopexy repositions the testis to the scrotum through one or two groin incisions, ensuring adequate vessel length with or without division of the cremasteric fibres and gubernacular bands, creates a dartos pouch between the skin and the scrotal wall (Shoemaker technique), and anchors the testis in the pouch. Laparoscopic orchidopexy is the standard approach for intra-abdominal testes, offering direct visualisation of the testicular vessels and anatomy; a staged Fowler-Stephens procedure (first laparoscopic ligation of testicular vessels 6 months before second-stage orchidopexy) is used when vessels are too short for single-stage descent.

Orchidopexy treats: unilateral or bilateral cryptorchidism (undescended testis) that has not resolved spontaneously by 6 months of corrected gestational age; palpable undescended testis in the inguinal canal or superficial inguinal ring — the most common site (90% of cases are palpable pre-operatively); non-palpable undescended testis requiring diagnostic laparoscopy to locate — may be intra-abdominal, just inside the internal inguinal ring (peeping testis), or absent (testicular agenesis or vanishing testis from pre-natal torsion); retractile testis (a normally positioned testis that retracts to the groin due to overactive cremasteric reflex) — usually does not require surgery but warrants monitoring; ectopic testis located in abnormal positions (perineum, femoral triangle, base of penis, opposite scrotum) — always requires orchidopexy; and secondary cryptorchidism (ascending testis) — a previously descended testis that migrates upward into the groin secondary to a persistent or new processus vaginalis or tethering, occurring in 1–7% of boys previously confirmed to have bilateral scrotal testes.

Current international guidelines (American Academy of Pediatrics, European Association of Paediatric Urology, British Association of Paediatric Surgeons) recommend orchidopexy be performed at 6–18 months of age, with a target of before 12–18 months to optimise testicular function and spermatogenic cell preservation. Earlier intervention was recommended after studies showed progressive loss of germ cells (Ad spermatogonia) after the first year of life in undescended testes, with improved fertility outcomes when surgery is performed early. Pre-operative evaluation includes clinical examination to determine palpability and location of the testis, ultrasound of the inguinal region (useful for confirming inguinal position and distinguishing from lymph node), and — for non-palpable testes — diagnostic laparoscopy is the definitive investigation (MRI and ultrasound cannot reliably locate an intra-abdominal testis). Hormonal stimulation with hCG or GnRH (gonadotropin-releasing hormone) may be used pre-operatively at some centres to aid descent but is not routinely recommended due to limited evidence. Boys presenting beyond infancy with untreated cryptorchidism benefit from orchidopexy at any age to reduce testicular malignancy risk and enable self-examination, even if fertility benefit is less certain.

Orchidopexy performed before 12–18 months of age optimises the following outcomes: preservation of spermatogenic potential — early surgery significantly increases the Ad spermatogonia count per tubule at orchidopexy compared to later surgery; fertility rates in men with unilateral cryptorchidism treated before 2 years approach those of the general population (90–95% paternity rate); bilateral undescended testes treated early have paternity rates of approximately 65–75%. Orchidopexy reduces the relative risk of testicular germ cell tumour (seminoma, non-seminoma) compared to untreated cryptorchidism — men with uncorrected cryptorchidism have 3–10 times the baseline risk; surgery before puberty may reduce but not eliminate this excess risk. Orchidopexy enables regular testicular self-examination — detecting potential malignancy at an earlier, more treatable stage. The procedure corrects associated anomalies simultaneously: associated patent processus vaginalis / inguinal hernia (present in 90% of undescended testes) is repaired at the same time. Psychological benefit of a normally appearing scrotum is significant.

Orchidopexy is generally a safe outpatient procedure. Testicular atrophy — post-operative loss of testicular blood supply causing progressive shrinkage — is the most serious complication, occurring in 1–2% of inguinal orchidopexy cases and in 5–15% of staged Fowler-Stephens orchidopexy for high intra-abdominal testes (where the testicular vessels are divided). Testicular re-ascent (the testis returns to an undescended position) occurs in 2–5% of orchidopexy cases, requiring repeat surgery. Wound infection affects less than 1% of cases. Injury to the vas deferens during dissection — potentially impairing future fertility — occurs in less than 1% of experienced surgeons' cases. Haematoma at the surgical site resolves spontaneously in the majority. Injury to the ilioinguinal nerve causing numbness of the inner thigh and scrotum affects 2–3% of patients. Despite surgery, men with a history of cryptorchidism have a moderately higher lifetime risk of testicular cancer compared to the general population and should perform monthly testicular self-examination from adolescence.

Orchidopexy in India costs USD 600–1,500 for open inguinal orchidopexy and USD 1,000–2,500 for laparoscopic orchidopexy (non-palpable testes), inclusive of surgeon fee, paediatric anaesthesia, day-case or 1-night hospitalisation, and follow-up. Staged Fowler-Stephens orchidopexy (2 laparoscopic procedures) costs USD 1,800–4,000 total. Leading paediatric urology and surgical centres include Apollo Children's Hospital, Narayana Health, Rainbow Children's Hospital, AIIMS Delhi, KEM Hospital Mumbai, and Amrita Hospital. In Thailand, orchidopexy costs USD 2,500–5,000; Turkey USD 2,000–4,500; Mexico USD 1,800–4,000. In the USA, paediatric orchidopexy costs USD 10,000–25,000 without insurance. UK NHS provides this procedure free of charge; private costs are GBP 3,500–7,000. India's large volume of paediatric surgical procedures, experienced paediatric urologists, and cost advantage of 70–80% versus the USA make it an attractive destination for families worldwide.

Treatment aims to achieve a normally positioned scrotal testis by 12–18 months of age to optimise fertility and allow cancer surveillance:

• Inguinal orchidopexy (standard for palpable inguinal UDT): An inguinal skin-crease incision exposes the spermatic cord and patent processus vaginalis (PPV), which is high-ligated. The cord is mobilised with careful preservation of the vas deferens and testicular vessels. A sub-dartos pouch is created in the ipsilateral hemi-scrotum, and the testis is secured within it. Bilateral UDT requires two separate surgical sessions. Success rate (testis remaining scrotal) exceeds 95% for inguinal testes.
• Laparoscopic orchidopexy (for non-palpable/intra-abdominal UDT): Laparoscopy first confirms the testis is present and its location (high inguinal, abdominal, or absent). Options include: (1) One-stage laparoscopic orchidopexy with extended cord mobilisation if there is enough vessel length; (2) Two-stage Fowler-Stephens orchidopexy — Stage 1: clip the spermatic vessels laparoscopically, wait 6 months for collateral blood supply via vas deferens vessels to develop; Stage 2: mobilise and transpose testis to scrotum using the preserved vasal pedicle. Two-stage Fowler-Stephens achieves scrotal positioning in 70–85% of cases.
• Hormonal therapy (GnRH analogues or hCG): Buserelin nasal spray (GnRH analogue, 4 weeks) or hCG injections (3 doses, 3 weeks) stimulates testosterone-driven descent in 15–25% of palpable low-lying testes. Used pre-operatively to increase testicular size and spermatogonia count, facilitating surgery. Not a substitute for orchidopexy if descent does not occur.
• Orchiectomy: Performed for absent testis (vanishing testis — absent at surgery with atrophic nubbins, usually from antenatal torsion), severely atrophic UDT identified laparoscopically (less than 50% normal size), or post-pubertal cryptorchid testes where malignant change risk exceeds surgical benefit. Testicular prosthesis offered at puberty for cosmetic and psychological benefit.

Follow-up after orchidopexy monitors testicular position, growth, and long-term cancer surveillance:

• 2-week wound review: Confirm testis is in the scrotum. Scrotal bruising and swelling are normal and resolve within 2 weeks. Wound check for infection. Pain well-controlled with regular paracetamol.
• 6-week review: Clinical orchidometry to measure testicular size. Testicular atrophy after orchidopexy (5–15%) results from vascular compromise at surgery; any size discrepancy versus the contralateral testis should be monitored and investigated with ultrasound.
• Annual review until puberty: Testicular size measurement at each visit. UDT and previously cryptorchid testes carry 4–6 times the general population risk of testicular germ cell tumour. Boys and parents should be taught testicular self-examination from puberty onwards. Any new lump requires urgent ultrasound and urology referral.
• Fertility counselling (adulthood): Unilateral orchidopexy before 18 months achieves near-normal spermatogenesis in most cases. Bilateral cryptorchidism carries higher subfertility risk even after timely surgery — semen analysis is appropriate in adulthood if fertility is a concern. Assisted reproduction options (IVF with ICSI) are available if significant fertility impairment is found.

Orchidopexy before 12–18 months is the evidence-based recommendation. Alternatives are limited:

• Hormonal therapy alone: GnRH analogues (buserelin) and hCG achieve testicular descent in 15–25% of cases — highest success for low palpable testes, lowest for high inguinal or abdominal testes. European guidelines recommend hormonal therapy primarily as a pre-surgical adjunct rather than a primary treatment, because failure rates are high and delayed orchidopexy (after 18 months) is associated with worse germ cell counts and fertility outcomes. Where descent does occur with hormones, surgical orchidopexy is avoided.
• Watchful waiting: Physiological testicular descent occurs in many premature and some term neonates by 3–6 months of age; observation until 6 months of corrected age is appropriate. Beyond 6 months, spontaneous descent is unlikely and any further waiting beyond 12 months is not recommended per current EAU and ESPU guidelines, as germ cell loss begins in the second year of life in undescended testes.